ReviewCellular and molecular life sciences : CMLS2017
Melatonin, mitochondria, and the metabolic syndrome.
Review in Cellular and molecular life sciences : CMLS, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Associations between the brain glymphatic system and mitochondrial (dys)function: a systematic review.Frontiers in neuroscience · 2025Pooled it
- Melatonin Administration Attenuates High-Fat-Diet-Induced Renal Damage in Wistar Rats.Biomolecules · 2025Article
- Physiological Conditions, Bioactive Ingredients, and Drugs Stimulating Non-Shivering Thermogenesis as a Promising Treatment Against Diabesity.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Melatonin mitigates ovarian aging through regulation of the YTHDF2/mActa biochimica et biophysica Sinica · 2025Article
- Association of serum biochemical parameters with growth performance and gut microbiota in large white pigs.Frontiers in veterinary science · 2025Article
- Factors associated with metabolic syndrome among adult residents in Dalian: a nested case-control study.Frontiers in endocrinology · 2025Article
- The clock is ticking on schizophrenia: a study protocol for a translational study integrating phenotypic, genomic, microbiome and biomolecular data to overcome disability.Frontiers in psychiatry · 2024Article
- Redox Biology of Melatonin: Discriminating Between Circadian and Noncircadian Functions.Antioxidants & redox signaling · 2022Review
- Melatonin ameliorates diabetic hyperglycaemia-induced impairment of Leydig cell steroidogenic function through activation of SIRT1 pathway.Reproductive biology and endocrinology : RB&E · 2022Article
- Immunomodulation of Oxidative Stress during Organ Donation Process: Preliminary Results.Healthcare (Basel, Switzerland) · 2022Article
- Melatonin and Pathological Cell Interactions: Mitochondrial Glucose Processing in Cancer Cells.International journal of molecular sciences · 2021Review
- Protective Effects of Flavonoids Against Mitochondriopathies and Associated Pathologies: Focus on the Predictive Approach and Personalized Prevention.International journal of molecular sciences · 2021Review
- The Coronavirus Disease 2019 (COVID-19): Key Emphasis on Melatonin Safety and Therapeutic Efficacy.Antioxidants (Basel, Switzerland) · 2021Review
- Melatonin Ameliorates Autophagy Impairment in a Metabolic Syndrome Model.Antioxidants (Basel, Switzerland) · 2021Article
- Potential Effects of Melatonin and Micronutrients on Mitochondrial Dysfunction during a Cytokine Storm Typical of Oxidative/Inflammatory Diseases.Diseases (Basel, Switzerland) · 2021Review
- Article
- Molecular Mechanisms of Melatonin-Mediated Cell Protection and Signaling in Health and Disease.Pharmaceutics · 2021Review
- Melatonin Regulates Differentiation of Sheep Brown Adipocyte Precursor CellsFrontiers in veterinary science · 2021Article
- Transcriptomic Insights into the Effect of Melatonin inAntioxidants (Basel, Switzerland) · 2020Article
- Nutrition, Bioenergetics, and Metabolic Syndrome.Nutrients · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A number of risk factors for cardiovascular disease including hyperinsulinemia, glucose intolerance, dyslipidemia, obesity, and elevated blood pressure are collectively known as metabolic syndrome (MS). Since mitochondrial activity is modulated by the availability of energy in cells, the disruption of key regulators of metabolism in MS not only affects the activity of mitochondria but also their dynamics and turnover. Therefore, a link of MS with mitochondrial dysfunction has been suspected since long. As a chronobiotic/cytoprotective agent, melatonin has a special place in prevention and treatment of MS. Melatonin levels are reduced in diseases associated with insulin resistance like MS. Melatonin improves sleep efficiency and has antioxidant and anti-inflammatory properties, partly for its role as a metabolic regulator and mitochondrial protector. We discuss in the present review the several cytoprotective melatonin actions that attenuate inflammatory responses in MS. The clinical data that support the potential therapeutical value of melatonin in human MS are reviewed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.